Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | Pomoč | SLO | ENG

Naslov:Clinical outcomes in stage III non-small cell lung cancer patients treated with durvalumab after sequential or concurrent platinum-based chemoradiotherapy : single institute experience
Avtorji:ID Vrankar, Martina (Avtor)
ID Stanič, Karmen (Avtor)
ID Jelerčič, Staša (Avtor)
ID Ćirić, Eva (Avtor)
ID Vodušek, Ana Lina (Avtor)
ID But-Hadžić, Jasna (Avtor)
Datoteke:.pdf PDF - Predstavitvena datoteka, prenos (394,39 KB)
MD5: C665D9711475D58C3B88CAD33970D606
 
Jezik:Angleški jezik
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:Logo OI - Onkološki inštitut Ljubljana
Povzetek:Chemoradiotherapy (ChT-RT) followed by 12-month durvalumab is the new standard treatment for unresectable stage III non-small cell lung cancer. Survival data for patients from everyday routine clinical practice is scarce, as well as potential impact on treatment efficacy of sequential or concomitant chemotherapy and the us-age of gemcitabine.Patients and methods. We retrospectively analysed unresectable stage III NSCLC patients who were treated with durvalumab after radical concurrent or sequential chemotherapy (ChT) from December 2017 and completed treat-ment until December 2020. We assessed progression free survival (PFS), overall survival (OS) and toxicity regarding baseline characteristic of patients.Results. Eighty-five patients with median age of 63 years of which 70.6% were male, 56.5% in stage IIIB and 58.8% with squamous cell carcinoma, were included in the analysis. Thirty-one patients received sequential ChT only, 51 patients received induction and concurrent ChT and 3 patients received concurrent ChT only. Seventy-nine patients (92.9%) received gemcitabine and cisplatin as induction chemotherapy and switched to etoposide and cisplatin during con-current treatment with radiotherapy (RT). Patients started durvalumab after a median of 57 days (range 12–99 days) from the end of the RT and were treated with the median of 10.8 (range 0.5–12 months) months. Forty-one patients (48.2%) completed treatment with planned 12-month therapy, 25 patients (29.4%) completed treatment early due to the toxicity and 16 patients (18.8%) due to the disease progression. Median PFS was 22.0 months, 12- and estimated 24-month PFS were 71% (95% CI: 61.2–80.8%) and 45.8% (95% CI: 32.7–58.9%). With the median follow-up time of 23 months (range 2–35 months), median OS has not been reached. Twelve- and estimated 24-month OS were 86.7% (95% CI: 79.5–93.9%) and 68.6% (95% CI: 57.2–79.9%).Conclusions. Our survival data are comparable with published research as well as with recently published real-world reports. Additionally, the regimen with gemcitabine and platinum-based chemotherapy as induction treatment was efficient and well tolerated.
Ključne besede:non-small cell lung cancer, stage III, chemoradiotherapy, durvalumab, acute toxicity
Status publikacije:Objavljeno
Verzija publikacije:Objavljena publikacija
Datum objave:01.01.2021
Založnik:Association of Radiology and Oncology
Leto izida:2021
Št. strani:str. 462-490, XI
Številčenje:Vol. 55, no. 4
Izvor:Ljubljana
PID:20.500.12556/DiRROS-19672 Novo okno
UDK:616.2
ISSN pri članku:1318-2099
COBISS.SI-ID:89454083 Novo okno
Avtorske pravice:by Authors
Datum objave v DiRROS:23.07.2024
Število ogledov:519
Število prenosov:125
Metapodatki:XML DC-XML DC-RDF
:
VRANKAR, Martina, STANIČ, Karmen, JELERČIČ, Staša, ĆIRIĆ, Eva, VODUŠEK, Ana Lina in BUT-HADŽIĆ, Jasna, 2021, Clinical outcomes in stage III non-small cell lung cancer patients treated with durvalumab after sequential or concurrent platinum-based chemoradiotherapy : single institute experience. Radiology and oncology [na spletu]. 2021. Vol. 55, no. 4, p. 462–490, xi. [Dostopano 11 april 2025]. Pridobljeno s: https://dirros.openscience.si/IzpisGradiva.php?lang=slv&id=19672
Kopiraj citat
  
Objavi na:Bookmark and Share


Podobna dela iz repozitorija:

Ni podobnih del
Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Gradivo je del revije

Naslov:Radiology and oncology
Skrajšan naslov:Radiol. oncol.
Založnik:Slovenian Medical Society - Section of Radiology, Croatian Medical Association - Croatian Society of Radiology
ISSN:1318-2099
COBISS.SI-ID:32649472 Novo okno

Nazaj